Growth & profitability
- Revenue has grown 56.6% per year over the past 5 years.
- Operating margin has expanded, at 11.9% in the latest year.
Financial health
- Operating income covered interest expense 1.1× in the latest year.
ARWR Financials Arrowhead Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $829M | -$2M | 0.0% | 11.9% | -0.3% | -0.1% | $157M | — | $227M |
| 2024 | $4M | -$599M | 0.0% | -16927.1% | -323.3% | -52.6% | -$604M | — | $103M |
| 2023 | $241M | -$205M | 0.0% | -85.2% | -75.7% | -26.8% | -$331M | — | $111M |
| 2022 | $243M | -$176M | 0.0% | -73.4% | -44.2% | -25.4% | -$189M | — | $108M |
| 2021 | $138M | -$141M | 0.0% | -107.8% | -34.5% | -19.8% | $148M | — | $184M |
| 2020 | $88M | -$85M | 0.0% | -105.9% | -18.3% | -16.2% | -$108M | — | $144M |
| 2019 | $169M | $68M | 0.0% | 36.3% | 27.8% | 19.4% | $161M | — | $222M |
| 2018 | $16M | -$54M | 0.0% | -346.5% | -56.8% | -48.8% | -$49M | — | $30M |
| 2017 | $31M | -$34M | 0.0% | -117.8% | -42.2% | -33.1% | -$32M | — | $25M |
| 2016 | — | -$82M | — | — | -85.5% | -63.8% | -$68M | — | — |
| 2015 | — | -$92M | — | — | -83.4% | -69.5% | — | — | — |
| 2014 | — | -$59M | — | — | -35.2% | -32.1% | — | — | — |
| 2014 | — | -$191M | — | — | -99.6% | -94.0% | — | — | — |
| 2013 | — | -$177M | — | — | -213.5% | -190.5% | — | — | — |
| 2013 | — | -$31M | — | — | -113.3% | -83.4% | — | — | — |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $75M | -$194M | 0.0% | -226.0% | -41.7% | -9.2% | -$181M | — | $55M |
| Mar '26 | $74M | -$133M | 0.0% | -191.6% | -21.6% | -5.9% | $82M | — | $189M |
| Dec '25 | $264M | $31M | 0.0% | 15.5% | 5.4% | 1.9% | $11M | — | $202M |
| Sep '25 | $256M | -$24M | 0.0% | 17.2% | -5.1% | -1.7% | $13M | — | $227M |
| Jun '25 | $28M | -$175M | 0.0% | -596.2% | -33.6% | -12.7% | -$157M | — | $130M |
| Mar '25 | $543M | $370M | 0.0% | 70.2% | 54.2% | 23.5% | $455M | — | $186M |
| Dec '24 | $3M | -$173M | 0.0% | -6456.5% | -329.1% | -17.1% | -$154M | — | $54M |
| Sep '24 | $0 | -$171M | — | — | -92.0% | -15.0% | -$162M | — | $103M |
| Jun '24 | $0 | -$171M | — | — | -51.7% | -19.3% | -$130M | — | $69M |
| Mar '24 | $0 | -$125M | — | — | -25.9% | -13.1% | -$126M | — | $128M |
| Dec '23 | $4M | -$133M | 0.0% | -3845.3% | -82.8% | -21.2% | -$186M | — | $58M |
| Sep '23 | $16M | -$110M | 0.0% | -673.0% | -40.4% | -14.3% | -$90M | — | $111M |
| Jun '23 | $16M | -$103M | 0.0% | -649.0% | -28.2% | -12.9% | -$67M | — | $105M |
| Mar '23 | $146M | $49M | 0.0% | 32.9% | 10.9% | 5.5% | -$59M | — | $135M |
| Dec '22 | $63M | -$41M | 0.0% | -67.4% | -11.0% | -4.6% | -$114M | — | $202M |
| Sep '22 | $32M | -$86M | 0.0% | -265.5% | -21.5% | -12.4% | -$101M | — | $108M |
| Jun '22 | $32M | -$72M | 0.0% | -224.9% | -15.9% | -9.6% | -$78M | — | — |
| Mar '22 | $152M | $44M | 0.0% | 27.4% | — | 6.3% | $58M | — | — |
| Dec '21 | $27M | -$63M | 0.0% | -230.8% | — | -9.8% | -$67M | — | — |
| Sep '21 | $38M | -$63M | 0.0% | -169.5% | -15.5% | -8.9% | -$32M | — | $184M |
Valuation over time
How the market has priced ARWR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 14.8× (Mar '23) to 14.7× (Sep '26).
P/S
Frequently asked questions
Is ARWR growing its revenue and profit?
Over the past 5 years, Arrowhead Pharmaceuticals, Inc.'s revenue has grown 56.6% per year. These are computed facts, not advice.
How much debt does ARWR have?
As of FY2025, Arrowhead Pharmaceuticals, Inc. reported — of total debt against $227M of cash; operating income covered interest expense 1.1×.
What is ARWR's profit margin?
In FY2025, gross margin was —, operating margin 11.9%, and net margin -0.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.